Clinical trials: Neoadjuvant Therapies
Non-Small Cell Lung Cancer, Immunotherapy
Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
This phase 1b/2a study evaluates the safety, feasibility, and efficacy of combining dupilumab (anti-IL-4Rα) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
- Trial name
- Dupi-Cemi (NCT06743581)
- Testing
- Cemiplimab, Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Oral Squamous Cell Carcinoma, Head and Neck Cancer
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
This is a phase 2, open-label, single-arm clinical trial evaluating neoadjuvant therapy with Becotatug vedotin (MRG003) combined with Pucotenlimab (HX008) in patients with previously untreated, resectable stage III-IVA oral…
- Conditions
- Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07766889
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer, Immunotherapy
Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study
The SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical…
- Conditions
- Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy, Thoracic Surgery
- Trial name
- SAVED LUNG (NCT06743555)
- Testing
- Observation without surgery, Standard-of-care surgery
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer
- Trial name
- NCT07448077
- Testing
- Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients…
- Trial name
- LUXUS0701 (NCT07720921)
- Testing
- Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Elderly Females, HER2 + Breast Cancer
Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
This is a single-center, interventional, prospective clinical study. A total of 45 patients aged ≥ 60 years with ECOG PS 0-1 who have histologically confirmed, treatment-naïve, unilateral primary invasive HER-2-positive breast…
- Conditions
- Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy
- Trial name
- NCT07695259
- Testing
- olaparib combined with trastuzumab and pertuzumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Wen-Ming Cao
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC)
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07601737
- Testing
- Nimotuzumab Injection, Tislelizumab, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma. type of study: clinical trial
- Trial name
- NCT06165380
- Testing
- Cardenilimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Li Zhang
HNSCC, Lysogenic HSV Virus
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
- Conditions
- HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT07010120
- Testing
- Tislelizumab, Afatinib, Lysogenic HSV virus.
- Where
- China
- Volunteers
- 29 people
- Sponsor
- West China Hospital
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapy，This study will examine…
- Trial name
- NCT06126640
- Testing
- SHR-A1811, Trastuzumab Emtansine
- Where
- 2 sites in China
- Volunteers
- 1,615 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer, Neoadjuvant Therapy
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing.
- Trial name
- NCT06909643
- Testing
- Artificial intelligence (AI)-based predictive model
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Small Cell Lung Cancer, Neoadjuvant Therapy
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody…
- Conditions
- Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
- Trial name
- NCT07359040
- Testing
- Ivonescimab, PD-1 Inhibitors
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
NSCLC, EGFR Positive Non-small Cell Lung Cancer
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
- Conditions
- NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
- Trial name
- NCT07622706
- Testing
- Firmonertinib 80mg qd oral for 8 weeks., Firmonertinib 160mg qd oral for 8 weeks., Firmonertinib 80mg qd oral for 16 weeks.
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cervical Cancer, Neoadjuvant Therapy
QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical…
- Conditions
- Cervical Cancer, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT07617818
- Testing
- QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Triple Negative Breast Cancer, Blood and Image Guided
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
- Conditions
- Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
- Trial name
- NCT07610525
- Testing
- Paclitaxel + Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small-Cell Lung Cancer, Neoadjuvant Therapy
Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial
This study is a multicenter, single-arm Phase II clinical trial, aiming to explore the safety and preliminary efficacy of oral paclitaxel solution combined with immune checkpoint inhibitors as a neoadjuvant regimen in elderly…
- Conditions
- Non-Small-Cell Lung Cancer, Neoadjuvant Therapy, Paclitaxel
- Trial name
- NCT07599163
- Testing
- Paclitaxel Oral Solution
- Volunteers
- 75 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
English Translation (Professional Medical Version) This study is a multicenter, prospective clinical trial designed to investigate the efficacy and safety of neoadjuvant therapy with trastuzumab plus pertuzumab combined with…
- Trial name
- NCT07589972
- Testing
- neoadjuvant therapy
- Volunteers
- 45 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer, Total Neoadjuvant Therapy
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
This study is a national multicenter, prospective randomized, placebo- controlled Phase III clinical trial designed to investigate the potential therapeutic benefit of immunotherapy combined with total neoadjuvant therapy (TNT)…
- Conditions
- Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, Immunotherapy
- Trial name
- NCT07113275
- Testing
- Short-course radiotherapy, Long-course radiotherapy, Capecitabine
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Tao Zhang
Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT).
- Conditions
- Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy, Radiotherapy
- Trial name
- NCT06758830
- Testing
- Radiation Therapy, Chemoradiotherapy, Consolidation Chemotherapy
- Where
- Lithuania
- Volunteers
- 400 people
- Sponsor
- National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Organ Preservation, Rectal Cancer Stage I
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized…
- Conditions
- Organ Preservation, Rectal Cancer Stage I, Total Neoadjuvant Treatment, Consolidation Therapy
- Trial name
- OPTION (NCT07563907)
- Testing
- TNT with additional consolidation chemotherapy followed by local excision, TNT followed by local excision
- Where
- South Korea
- Volunteers
- 292 people
- Sponsor
- Seoul National University Hospital